MedTrace Logo

Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3

NCT03819660 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-11-30

Study results available
· View outcomes & findings →

Summary

A long term safety study of amifampridine phosphate in patients with spinal muscular atrophy (SMA) Type 3.

Conditions

  • Spinal Muscular Atrophy Type 3

Interventions

DRUG

Amifampridine Phosphate 10 MG Oral Tablet

Oral tablets

Sponsors & Collaborators

Principal Investigators

  • Lorenzo Maggi, MD · Carlo Besta Institute, Milan, Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-07
Primary Completion
2021-09-13
Completion
2021-09-13
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03819660 on ClinicalTrials.gov